secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2023-10-06T23:59:59+00:00
Accession:  0001437749-23-027849
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Atossa Therapeutics CFO Greg Weaver resigns; Heather Rees appointed as principal financial officer
--------------------------------------------------------------------------------

- Greg Weaver resigned as EVP and CFO effective Oct 5, 2023; resignation not due to disagreement with company.
- Company waived 30-day notice period, accelerating departure to Oct 5.
- Heather Rees, previously VP Finance and Accounting, appointed as principal financial and accounting officer.
- Rees has been with company since 2017 as controller, then VP; prior experience includes Deloitte and independent consulting.
- Weaver's termination also served as resignation from Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000143774923027849/0001437749-23-027849-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000143774923027849/atos20231003_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-027849

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer